6.639 an Journal by MDPI

Ovarian Biomarkers, Diagnostic and Therapeutic Technologies

Guest Editors: Message from the Guest Editors

Dr. Andrew Stephens Ovarian cancer remains one of the most lethal of Centre for Cancer Research, gynaecological malignancies, characterised in most Hudson Institute of Medical Research, Victoria VIC 3168, patients by recurrent, persistent disease and the rapid Australia acquisition of chemo-resistance. Substantial molecular School of Translational Sciences, heterogeneity and co-existing phenotypes at diagnosis Monash University, Victoria VIC further complicate treatment choices and efficacy. 3800, Australia andrew.n.stephens@ Early diagnosis—ideally of pre-cancerous lesions, and hudson.org.au particularly in asymptomatic women—remains a major challenge in ovarian cancer management. Equally as Dr. Maree Bilandzic Centre for Cancer Research, important, prognostic and predictive approaches are Hudson Institute of Medical required to detect recurrence and enhance therapeutic Research, Victoria VIC 3168, management for patients in whom primary care is likely to Australia fail. Combined with approaches to identify new druggable School of Translational Sciences, Monash University, Victoria VIC targets and therapeutic strategies—whether synergistic or 3800, Australia stand-alone—research is poised to exert a substantial and [email protected] positive impact over clinical ovarian cancer management. This Special Issue will focus on emerging technologies with the potential to improve the diagnosis, prognostic Deadline for manuscript evaluation and therapeutic management ovarian cancers. submissions: 28 December 2021

mdpi.com/si/77485 SpeciaIslsue IMPACT FACTOR 6.639 an Open Access Journal by MDPI

Editor-in-Chief Message from the Editor-in-Chief

Prof. Dr. Samuel C. Mok Cancers is an international online journal addressing both Department of Gynecologic clinical and basic science issues related to cancer research. Oncology and Reproductive The journal is publishing in Open Access format, which will Medicine, The University of Texas MD Anderson Cancer Center, certainly evolve to ensure that the journal takes full Houston, TX 77030, USA advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions. High Visibility: indexed within , SCIE (), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases. Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q2 (Oncology)

Contact Us

Cancers Tel: +41 61 683 77 34 mdpi.com/journal/cancers MDPI, St. Alban-Anlage 66 Fax: +41 61 302 89 18 [email protected] 4052 Basel, Switzerland www.mdpi.com @Cancers_MDPI